PUMA BIOTECHNOLOGY, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M |
| Cost of revenue | $58.2M | $64.4M | $62.7M | $55.1M | $63.7M |
| Selling, general & administrative | $70.8M | $80.2M | $89.9M | $90.0M | $116.3M |
| Research and development | $62.1M | $54.9M | $50.4M | $52.2M | $71.9M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M |
| Interest expense | $6.6M | $12.5M | $13.3M | $11.6M | $12.8M |
| Pretax income | $35.8M | $24.1M | $22.7M | $457,000 | -$28.8M |
| Income tax expense | $4.7M | -$6.2M | $1.1M | $455,000 | $324,000 |
| Net income | $31.1M | $30.3M | $21.6M | $2,000 | -$29.1M |
| Balance Sheet | |||||
| Cash and equivalents | $29.6M | $69.2M | $84.6M | $76.2M | $63.1M |
| Current assets | $162.7M | $147.7M | $156.2M | $134.3M | $140.0M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M |
| Current liabilities | $81.3M | $96.1M | $99.4M | $77.5M | $109.6M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M |
| Total debt | $102.0M | $102.0M | $102.0M | $102.0M | $102.0M |
| Stockholders' equity | $130.3M | $92.1M | $53.4M | $21.6M | -$2.4M |
| Cash Flow Statement | |||||
| Cash from operations | $41.8M | $38.9M | $27.0M | -$15.8M | $20.6M |
| Depreciation and amortization | $400,000 | $400,000 | $400,000 | $600,000 | $700,000 |
| Stock-based compensation | $6.9M | $8.2M | $10.2M | $11.8M | $32.6M |
| Capital expenditure | $71,000 | $56,000 | $140,000 | $0 | $0 |
| Free cash flow | $41.7M | $38.9M | $26.9M | -$15.8M | $20.6M |
| Impairments | $0 | $0 | $625,000 | $0 | $0 |
Shares outstanding 50.9M · Free float 83.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.